Publications by authors named "Sonya Elizabeth Craig"
Article Synopsis
- Obstructive sleep apnea (OSA) often causes excessive daytime sleepiness (EDS), and pitolisant, a medication that targets histamine receptors, was tested for its efficacy in treating this issue in patients with moderate to severe OSA.
- In a clinical trial with 361 participants, pitolisant was administered in varying doses up to 40 mg daily for 12 weeks, showing a significant reduction in EDS as measured by the Epworth Sleepiness Scale compared to a placebo.
- The study found that pitolisant was well tolerated and improved not only daytime sleepiness but also reaction times and overall patient satisfaction, regardless of whether patients used continuous positive airway pressure (CPAP) therapy.
Background: Continuous positive airway pressure (CPAP) for symptomatic obstructive sleep apnoea (OSA) improves sleepiness and reduces vascular risk, but such treatment for the more prevalent, minimally symptomatic disease is contentious.
Methods: This multicentre, randomised controlled, parallel, hospital-based trial across the UK and Canada, recruited 391 patients with confirmed OSA (oxygen desaturation index >7.5/h) but insufficient symptoms to warrant CPAP therapy.